StemCells Inc. (STEM) Announces First High-Dose Patient Transplanted in Phase 1/2 Clinical Trial in Dry Age-Related Macular Degeneration
9/12/2013 9:23:27 AM
NEWARK, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced dosing of the first high-dose patient in the Company's Phase I/II clinical trial in dry age-related macular degeneration (AMD). The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with one million HuCNS-SC® cells (purified human neural stem cells). The first four patients each received a dose of 200,000 cells. An independent Data Safety Monitoring Committee conducted a review of the trial data to date, and found no safety issues to preclude the trial from proceeding to the high dose.
Help employers find you! Check out all the jobs and post your resume.
comments powered by